FDA Takes Enforcement Action Regarding Genzyme's Allston Plant - - BioPharm International

ADVERTISEMENT

FDA Takes Enforcement Action Regarding Genzyme's Allston Plant


The US Food and Drug Administration has notified Genzyme Corporation (Cambridge, MA) that it intends to take enforcement action to ensure that products manufactured at its Allston, MA, plant are made in compliance with good manufacturing practice regulations. The FDA enforcement action will likely result in a consent decree, under which a third party would inspect and review the plant's operation for an extended period and certify compliance with FDA regulations. Under the consent decree, Genzyme also would be required to make payments to the government and could incur other costs.

Based on its initial communication with the agency and the medical need for patients, Genzyme expects that shipments of Cerezyme (imiglucerase for injection) and Fabrazyme (agalsidase beta), which are manufactured in Allston, will continue uninterrupted during the period of the enforcement action. In addition, Genzyme expects that shipments of Myozyme (alglucosidase alfa) produced at the 160-L scale, which is filled and finished in Allston, will continue uninterrupted. The discussions with the FDA are expected to occur over the next several weeks.

Previous coverage
FDA Approves Shire's New Gaucher Drug

Shire Files Marketing Applications for Fabry and Gaucher Disease Drugs

Genzyme Outsources Fill-Finish Operations to Hospira

FDA Warns of Genzyme Product Contamination

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here